A carregar...
Rituximab, ofatumumab and other monoclonal anti‐CD20 antibodies for chronic lymphocytic leukaemia
BACKGROUND: Chronic lymphocytic leukaemia (CLL) accounts for 25% of all leukaemias and is the most common lymphoid malignancy in western countries. Standard treatments include mono‐ or polychemotherapies, usually combined with monoclonal antibodies such as rituximab or alemtuzumab. However, the impa...
Na minha lista:
| Publicado no: | Cochrane Database Syst Rev |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley & Sons, Ltd
2012
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6485963/ https://ncbi.nlm.nih.gov/pubmed/23152253 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/14651858.CD008079.pub2 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|